These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29474999)

  • 41. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy.
    Hussl A; Mahlknecht P; Scherfler C; Esterhammer R; Schocke M; Poewe W; Seppi K
    Mov Disord; 2010 Oct; 25(14):2444-9. PubMed ID: 20878992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease.
    Rascol O; Sabatini U; Fabre N; Senard JM; Simonetta-Moreau M; Montastruc JL; Clanet M; Rascol A
    Mov Disord; 1995 Mar; 10(2):163-70. PubMed ID: 7753058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ
    Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Lu Z; Wang J; Li M; Liu Q; Wei D; Yang M; Kong L
    Chem Biol Interact; 2014 Nov; 223():18-26. PubMed ID: 25242684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comment on Numao et al.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Picillo M; Barone P; Erro R; Spina E; Pellecchia MT
    Parkinsonism Relat Disord; 2014 Jun; 20(6):680-1. PubMed ID: 24630925
    [No Abstract]   [Full Text] [Related]  

  • 50. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease.
    Nicoletti G; Rizzo G; Barbagallo G; Tonon C; Condino F; Manners D; Messina D; Testa C; Arabia G; Gambardella A; Lodi R; Quattrone A
    Radiology; 2013 Jun; 267(3):843-50. PubMed ID: 23329659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy.
    Hara K; Watanabe H; Ito M; Tsuboi T; Watanabe H; Nakamura R; Senda J; Atsuta N; Adachi H; Aiba I; Naganawa S; Sobue G
    Parkinsonism Relat Disord; 2014 Feb; 20(2):157-61. PubMed ID: 24172606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.
    Seppi K; Scherfler C; Donnemiller E; Virgolini I; Schocke MF; Goebel G; Mair KJ; Boesch S; Brenneis C; Wenning GK; Poewe W
    Arch Neurol; 2006 Aug; 63(8):1154-60. PubMed ID: 16908744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy.
    Reginold W; Lang AE; Marras C; Heyn C; Alharbi M; Mikulis DJ
    Parkinsonism Relat Disord; 2014 Feb; 20(2):222-5. PubMed ID: 24239142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
    Bottero V; Santiago JA; Potashkin JA
    J Parkinsons Dis; 2018; 8(4):529-537. PubMed ID: 30248063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.
    Kanazawa M; Tada M; Onodera O; Takahashi H; Nishizawa M; Shimohata T
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1149-51. PubMed ID: 23916652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With (123) I-FP-CIT SPECT.
    Bae YJ; Kim JM; Kim E; Lee KM; Kang SY; Park HS; Kim KJ; Kim YE; Oh ES; Yun JY; Kim JS; Jeong HJ; Jeon B; Kim SE
    Mov Disord; 2016 May; 31(5):684-92. PubMed ID: 26990970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy.
    Berganzo K; Tijero B; Somme JH; Llorens V; Sánchez-Manso JC; Low D; Iodice V; Vichayanrat E; Mathias CJ; Lezcano E; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2012 Jan; 18(1):45-8. PubMed ID: 21908227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.